The Valley Desk

ReviewCancerPublished

Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Fox Chase Cancer Center, with Temple Health linked by the institution reference. Affiliation source

Publication record

Type
Review
Venue
Cancer
Published
Subject terms
T-Lymphocytes; Humans; Lung Neoplasms; Membrane Proteins; Antibodies, Bispecific; Immunotherapy; Small Cell Lung Carcinoma; Cytokine Release Syndrome; Safety Profile; Adverse Event Management; Tarlatamab; Dellphi‐301
PubMed ID
39876075
PubMed Central ID
PMC11775405
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal